Patient perception and approval of faecal microbiota transplantation (FMT) as an alternative treatment option for obesity

被引:13
|
作者
Gundling, F. [1 ]
Roggenbrod, S. [1 ]
Schleifer, S. [1 ]
Sohn, M. [2 ]
Schepp, W. [1 ]
机构
[1] Tech Univ Munich, Dept Gastroenterol Hepatol & Gastrointestinal Onc, Acad Teaching Hosp Bogenhausen, Englschalkinger St 77, D-81925 Munich, Germany
[2] Univ Munich, Dept Visceral Surg, Acad Teaching Hosp Bogenhausen, Munich, Germany
来源
OBESITY SCIENCE & PRACTICE | 2019年 / 5卷 / 01期
关键词
Fecal microbiota transfer; microbiota obesity; weight loss endoscopy trial (WET); ULCERATIVE-COLITIS; GUT MICROBIOTA; ENERGY-BALANCE; WEIGHT-LOSS; MECHANISMS; DIET;
D O I
10.1002/osp4.302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Fecal microbiota transplantation (FMT) represents a treatment option for some diseases, e.g. recurring Clostridium difficile-associated colitis. However, there is also evidence that FMT can be effective in treating obesity. This pilot study established the approval and willingness of obese patients to undergo FMT. Methods We conducted a survey of adults with obesity using a questionnaire containing 21 both multiple choice and open questions was dispatched to a cohort of 101 persons with obesity. It included questions aiming at the process of FMT itself, donors as well as possible concerns. Additionally aspects of social background and disease activity were dealt with. Results The response rate amounted to 30.1% (n = 31). In our population, mean BMI was 40.5 kg/m(2) while the vast majority already tried out treatment modalities to lose weight before. 25.8% of persons with obesity were aware of FMT. 62.1% were willing to undergo FMT if the donor was healthy and anonymous while only 6.9% clearly refused this option. Sixty preferred an anonymous donor or a person proposed by their doctor while colonoscopy was the preferred application by 76.7%. The absence of risks of the procedure (47.8%) formed the principal motivation while reduction of medication was considered as least important reason (in 26.1). Insufficient testing of the faeces concerning infections raised the most concerns (in 61.6%). Conclusion For the majority of the persons with obesity surveyed FMT represents a treatment option. Approximately two thirds of the questionees would consider FMT as an alternative treatment option, even in spite of a satisfactory disease response to current standard therapies. Unsurprisingly there are concerns in regard to the transmission of possible infectious agents as well as to the hygieneic implementation of FMT itself.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 50 条
  • [41] A case report looking at the effects of faecal microbiota transplantation in a patient with bipolar disorder
    Hinton, Russell
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2020, 54 (06): : 649 - 650
  • [42] FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR THE TREATMENT OF IMMUNE-MEDIATED DIARRHEA AND COLITIS: A CASE SERIES
    Elkrief, Arielle
    Peled, Jonathan U.
    Hellmann, Matthew D.
    Chaft, Jamie E.
    Eng, Juliana
    Motzer, Robert
    Mendelsohn, Robin
    Chapman, Paul B.
    Faleck, David M.
    GASTROENTEROLOGY, 2021, 160 (06) : S17 - S17
  • [43] DEVELOPMENT OF A LICENCED FAECAL MICROBIOTA TRANSPLANT SERVICE FOR PATIENT TREATMENT IN THE NHS
    McCune, Victoria L.
    Quraishi, Mohammed Nabil
    Manzoor, Susan
    Shabir, Sahida
    Hawkey, Peter M.
    Iqbal, Tariq H.
    GUT, 2019, 68 : A222 - A223
  • [44] Faecal microbiota transplantation (FMT) in IBS using a super-donor: A randomised, double-blind placebo-controlled study
    El-Salhy, M.
    Hausken, T.
    Gilja, O. H.
    Kristoffersen, A.
    Hatlebakk, J. G.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [45] Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?
    Xiang, Liyuan
    Ding, Xiao
    Li, Qianqian
    Wu, Xia
    Dai, Min
    Long, Chuyan
    He, Zhi
    Cui, Bota
    Zhang, Faming
    MICROBIAL BIOTECHNOLOGY, 2020, 13 (03): : 760 - 769
  • [46] The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy
    de Stefano, Maria Chiara
    Mazzanti, Benedetta
    Vespasiano, Francesca
    Lombardini, Letizia
    Cardillo, Massimo
    ANTIBIOTICS-BASEL, 2022, 11 (04):
  • [47] Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease
    Quraishi, M. N.
    Shaheen, W.
    Oo, Y. H.
    Iqbal, T. H.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 199 (01): : 24 - 38
  • [48] Statins in lung transplantation: A treatment option for every patient?
    Verleden, Geert M.
    Vos, Robin
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (09): : 936 - 937
  • [49] Faecal microbiota transplantation for the treatment of acute haemorrhagic diarrhoea syndrome in two dogs
    Wen, Tsung Fei
    Cho, Ying Chu
    Li, Chia Yin
    VETERINARY RECORD CASE REPORTS, 2022, 10 (02):
  • [50] Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?
    Fairhurst, Natalie Grace
    Travis, Simon P. L.
    INTESTINAL RESEARCH, 2018, 16 (02) : 209 - 215